Skip to main content
Premium Trial:

Request an Annual Quote

Sharat Singh, Christopher Maki, David Gelfand, Alnoor Shivji, Michael Mullenix, Gabriella Szekely-Klepser, Martin Mackay, Corey Goodman, Briggs Morrison, Jeff Kindler

WaferGen Biosystems this week appointed Sharat Singh as senior vice president of research and development and Christopher Maki as vice president of worldwide sales.
Singh is establishing and directing a core technology team charged with the development and commercialization of the company's SmartChip product. In this role, he will work closely with David Gelfand, WaferGen's chief scientific officer.
In addition, Singh, who will report directly to Alnoor Shivji, WaferGen's chairman and chief executive officer, will oversee the ongoing development of WaferGen's currently marketed SmartSlide platform.
Prior to joining WaferGen, Singh served as chief scientific officer at Aclara Biosciences.
Maki will be responsible for marketing WaferGen's SmartSlide product to target customers in the areas of live cell imaging and stem cell research. At the same time, he will be charged with developing and implementing a long-term global sales strategy for the introduction of the SmartChip product.
Maki joins WaferGen following more than six years at Molecular Devices (now part of MDS). At Molecular Devices, Maki most recently served as director of sales, research imaging, and high content screening.
Prior to his work with Molecular Devices, Maki served as northeast regional sales manager of Universal Imaging. He has also held various research positions at the Vollum Institute for Advanced Biomedical Research and the University of Pennsylvania.

Assay Designs this week announced that Michael Mullenix has joined the company as vice president for research and development.
Prior to joining Assay Designs, Mullenix was a principal scientist in Amgen’s clinical immunology group. Prior to joining Amgen, Mullenix held a series of R&D leadership positions with Molecular Staging, Becton Dickinson, and Strategic Diagnostics.
Assay Designs also announced this week that Gabriella Szekely-Klepser has joined the company as vice president of science and technology. Szekely-Klepser was previously an associate research fellow at Pfizer Global R&D, where she most recently was leader of the translational research biomarker implementation and biologics bioanalytical groups. Prior to her six years at Pfizer, Szekely-Klepser held various R&D positions at 3M.

Pfizer this week named Martin Mackay as president of Pfizer Global Research and Development; Corey Goodman as director if its new independent, stand-alone biotherapeutics and bioinnovation center; and Briggs Morrison, who held senior research and development positions at Merck, as senior vice president of clinical developmentfor the PGRD pipeline. (see also News Scan, this issue
Mackay and Goodman will report to Pfizer CEO Jeff Kindler and become members of the company’s executive leadership team.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.